KRSA
Korsana Biosciences, Inc.
+2.21 (+7.08%)33.44USD11.2K成交股數157M市值–本益比(近四季)78.5股價營收比–營收年增(近四季)–下次財報
財報 SEC XBRL 申報值 · 美元 · 財年於 12 月結束
逐季數字是 10-Q 的單季值;財年第四季 XBRL 只有年度值,這裡用年度減前三季推算。年增率比的是去年同一會計季。
營收與利潤率近 16 季
稀釋 EPS近 16 季 · 美元
現金流近 16 季
股東回饋近 16 季 · 庫藏股與股利
損益表 逐季 · 最新在左 · 小字是年增率
| 科目 | 26Q2 | 26Q1 | 25Q4 | 25Q3 | 25Q2 | 25Q1 | 24Q3 | 24Q2 | 24Q1 | 23Q4 | 23Q3 | 23Q2 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 營收 | – | 0.00-100% | 1.0M+428% | 875K | 93K | 81K | 194K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| 營業成本 | – | – | – | – | – | – | – | – | – | – | – | – |
| 毛利 | – | – | – | – | – | – | – | – | – | – | – | – |
| 毛利率 | – | – | – | – | – | – | – | – | – | – | – | – |
| 研發費用 | – | 730K | 519K | 348K | 56K | 36K | 81K | 105K | 44K | 24K | 580K | 339K |
| 銷售管理費用 | 1.8M | 2.5M | 1.3M | 1.5M | 1.7M | 1.5M | 1.2M | 1.3M | 1.6M | 1.8M | 2.1M | 1.5M |
| 營業利益 | −1.8M+6% | −3.2M+120% | −838K-26% | −1.0M-27% | −1.7M+3% | −1.5M-19% | −1.1M-81% | −1.4M-26% | −1.6M | −1.8M | −6.0M | −1.9M |
| 營業利益率 | – | – | -81.8% | -115.0% | -1,797.8% | -1,798.8% | -581.4% | – | – | – | – | – |
| 稅後淨利 | −1.8M+442% | −3.2M+122% | −799K+11% | −976K-26% | −324K-79% | −1.4M-16% | −723K-110% | −1.3M-68% | −1.5M | −1.7M | 7.6M | −4.2M |
| 淨利率 | – | – | -78.0% | -111.5% | -348.4% | -1,764.2% | -372.7% | – | – | – | – | – |
| 稀釋 EPS | -0.41+273% | -0.76+36% | -0.14-52% | -0.30-43% | -0.11-82% | -0.56-1033% | -0.29-111% | -0.53-71% | -0.62 | 0.06 | 2.72 | -1.83 |
| 稀釋股數 | 4.3M | 4.2M | 3.2M | 3.2M | 3.1M | 2.6M | 2.5M | 2.5M | 2.5M | 2.3M | 2.8M | 2.3M |
資產負債表 期末餘額
| 科目 | 26Q2 | 26Q1 | 25Q4 | 25Q3 | 25Q2 | 25Q1 | 24Q3 | 24Q2 | 24Q1 | 23Q4 | 23Q3 | 23Q2 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 現金與約當現金 | 1.4M | 2.8M | 3.2M | 4.6M | 3.0M | 3.6M | 2.9M | 4.6M | 5.7M | 7.6M | 9.1M | 5.6M |
| 應收帳款 | 0.00 | 0.00 | 1.0M | 100K | 525K | 581K | 44K | – | – | 0.00 | 0.00 | 0.00 |
| 存貨 | – | – | – | – | – | – | – | – | – | – | – | – |
| 總資產 | 6.9M | 8.5M | 10.0M | 10.4M | 9.4M | 9.8M | 8.9M | 10.1M | 11.4M | 13.4M | 15.2M | 10.1M |
| 有息負債 | – | – | – | – | – | – | – | – | – | – | – | – |
| 總負債 | – | – | – | – | – | – | – | – | – | – | – | – |
| 股東權益 | 5.1M | 6.8M | 9.1M | 9.5M | 8.6M | 8.8M | 8.2M | 8.8M | 9.9M | 11.3M | 12.9M | 5.2M |
| 負債比 | – | – | – | – | – | – | – | – | – | – | – | – |
| 淨現金(現金 − 有息負債) | – | – | – | – | – | – | – | – | – | – | – | – |
現金流量表 單季
| 科目 | 26Q2 | 26Q1 | 25Q4 | 25Q3 | 25Q2 | 25Q1 | 24Q3 | 24Q2 | 24Q1 | 23Q4 | 23Q3 | 23Q2 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 營業現金流 | – | −1.2M+21% | – | – | – | −968K | – | – | −1.9M | – | – | – |
| 資本支出 | – | 66K | – | – | – | 0.00 | – | – | – | – | – | – |
| 自由現金流 | – | −1.2M+28% | – | – | – | −968K | – | – | – | – | – | – |
| 折舊攤銷 | – | – | – | – | – | – | – | – | – | – | – | – |
| 買回庫藏股 | – | – | – | – | – | – | – | – | – | – | – | – |
| 現金股利 | – | – | – | – | – | – | – | – | – | – | – | – |
| 自由現金流率 | – | – | – | – | – | -1,195.1% | – | – | – | – | – | – |
營收拆解 2025 年度 10-K 的分部揭露 · 年增對前一年度
產品／服務2025 年度 · 2.1M
| License Agreement | 1.0M | 48.2% | -42.9% |
|---|---|---|---|
| Purchase Agreement | 800K | 38.6% | – |
| Option Agreement | 274K | 13.2% | +9.6% |
各維度的加總不一定等於合併營收:分部有時含內部交易、地區有時只揭露主要國家。挑的是加總最接近合併營收的那個標籤。
年度 10-K
| 財年 | 營收 | 年增 | 稅後淨利 | 淨利率 | 稀釋 EPS | 自由現金流 |
|---|---|---|---|---|---|---|
| FY2025 | 2.1M | +3.7% | −3.5M | -170.1% | -1.11 | – |
| FY2024 | 2.0M | – | −3.1M | -152.9% | -1.21 | – |
| FY2023 | 0.00 | -100.0% | −5.3M | –% | -2.25 | – |
| FY2022 | 297K | -92.5% | −44.1M | -14,841.1% | -20.28 | −40.6M |
| FY2021 | 3.9M | +71.7% | −51.6M | -1,310.2% | -1.32 | −36.5M |
| FY2020 | 2.3M | -49.1% | −77.8M | -3,388.6% | -2.56 | −74.0M |
| FY2019 | 4.5M | – | −123M | -2,729.3% | -4.49 | −109M |
| FY2018 | – | – | −115M | –% | -4.21 | −101M |